Most everybody wants the best deal for the money, but not everybody wants to settle for some potential options being excluded from the deal–no matter the cost of those options. So it goes in the continuing debate over comparative effectiveness... 

Chuck Grassley made news yesterday when he fired off a few shots at President Obama from his Twitter feed. The tweets were on health reform — a subject on which Grassley’s been playing a key role from his perch as the ranking Republican on... 

President Obama is trying to put some numbers on his argument that spending a lot of money on health reform in the short run will lead to savings over the long haul. A report out from the president’s economic advisers today makes the “economic... 

Today we get a follow-up to last month’s rather vague promise from a kitchen sink of health-care players to slow the rise of costs in the coming decade. Here’s today’s letter from (deep breath) AHIP, the AMA, the American Hospital Association,... 

A recent pledge by major players in the health industry to slow the growth of health costs in the U.S. may run into a significant hurdle: It could be illegal to promise to cap health spending in a coordinated way. It seems a bit counterintuitive. But... 

An oft-repeated phrase during the current debate over health reform: We’re not going to repeat the mid-1990s. Those who are pushing for reforms are trying to have an “open” process and industry players are vowing not to use scare tactics... 

After seeing its health-insurance premiums increase to more than $800 a month per employee from about $200 five years ago, Commerce Welding & Manufacturing Co. decided to drop coverage in December, marking the first time in the 64-year-history of... 

It’s not often the Health Blog is summoned to meet with a British lord. But Lord Darzi of Denham called us in the other day to vent some steam about U.S. ads that attack British health care. Darzi, a surgeon and top official in Britain’s Department... 

Articles are out this morning on Nancy-Ann DeParle and Peter Orszag, two major players on health reform for Obama, both of whom are working on issues that worry players in the industry. Politico details Nancy-Ann DeParle’s focus on keeping the... 

It’s been one thing after the next since Daiichi Sankyo’s deal last year for control of Indian generics maker Ranbaxy, including the FDA’s banning imports from certain Ranbaxy plants and accusing the company of falsifying data. The...